(Total Views: 496)
Posted On: 10/19/2021 2:35:16 PM
Post# of 154147
That "going concern" stuff is boilerplate that many if not most small biotechs put in, while they are in the pre-revenue stage. In CYDY's case, it's the small-revenue stage, soon to be the lots-more-revenue stage.
I'm going to pretend to be the judge musing about whether to grant the injunction, as fantasized by Rosenbaum et al:
"hmmm. I wrote a decision of over 100 pages, explaining how 13D failed to disclose crucial information, did not conform to the By-Laws, and tried using "gamesmanship" to prevent CYDY from finding out about their conflicts of interest. I wrote this so that it would set an important precedent, and would be extraordinarily unlikely to be overturned on appeal.
Okay, I'll grant the injunction."
I'm going to pretend to be the judge musing about whether to grant the injunction, as fantasized by Rosenbaum et al:
"hmmm. I wrote a decision of over 100 pages, explaining how 13D failed to disclose crucial information, did not conform to the By-Laws, and tried using "gamesmanship" to prevent CYDY from finding out about their conflicts of interest. I wrote this so that it would set an important precedent, and would be extraordinarily unlikely to be overturned on appeal.
Okay, I'll grant the injunction."
(6)
(0)
